Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

Cancer Immunology, Immunotherapy

Volumn 57, Issue 12, 2008, Pages 1849-1859

  Zhu, Dan ^a   Corral, Laura G ^a   Fleming, Yuedi W ^a   Stein, Bernd ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Co culture model; IMiDs immunomodulatory drugs; Tumor cell apoptosis

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; CD56 ANTIGEN; DOCETAXEL; LENALIDOMIDE; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL ACTIVITY; CELL POPULATION; CELL TYPE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; THALIDOMIDE;

EID: 52549088421     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0512-7     Document Type: Article

References (38)

1. A Bamias MA Dimopoulos 2005 Thalidomide and immunomodulatory drugs in the treatment of cancer Expert Opin Investig Drugs 14 45 55
2. JB Bartlett K Dredge AG Dalgleish 2004 The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 314 322
3. JB Bartlett A Michael IA Clarke K Dredge S Nicholson H Kristeleit A Polychronis H Pandha GW Muller DI Stirling J Zeldis AG Dalgleish 2004 Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers Br J Cancer 90 955 961
4. JB Bartlett A Tozer D Stirling JB Zeldis 2005 Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide Br J Cancer 93 613 619
5. Bartlett JB, Wu L, Adams M, Schafer P, Muller G, Stirling D (2007) lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. Paper presented at 2007 ASCO annual meeting abstract 3023
6. SM Chidrawar N Khan YL Chan L Nayak PA Moss 2006 Ageing is associated with a decline in peripheral blood CD56bright NK cells Immun Ageing 3 10
7. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55
8. LG Corral G Kaplan 1999 Immunomodulation by thalidomide and thalidomide analogues Ann Rheum Dis 58 Suppl 1 I107 I113
9. FE Davies N Raje T Hideshima S Lentzsch G Young YT Tai B Lin K Podar D Gupta D Chauhan SP Treon PG Richardson RL Schlossman GJ Morgan GW Muller DI Stirling KC Anderson 2001 Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 98 210 216
10. K Dredge JB Marriott CD Macdonald HW Man R Chen GW Muller D Stirling AG Dalgleish 2002 Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects Br J Cancer 87 1166 1172
11. K Dredge R Horsfall SP Robinson LH Zhang L Lu Y Tang MA Shirley G Muller P Schafer D Stirling AG Dalgleish JB Bartlett 2005 Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvasc Res 69 56 63
12. K Fischer A Mackensen 2003 The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity Methods 31 135 142
13. Y Wang D Zhu L Corral W Hong B Stein 2005 IMiDs enhance tumor cell apoptosis in tumor/PBMC co-cultures Proc Am Assoc Cancer Res 46 190 191
14. Z Gu J Yamashiro E Kono RE Reiter 2005 Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism Cancer Res 65 9495 9500
15. T Hayashi T Hideshima M Akiyama K Podar H Yasui N Raje S Kumar D Chauhan SP Treon P Richardson KC Anderson 2005 Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application Br J Haematol 128 192 203
16. FJ Hernandez-Ilizaliturri N Reddy B Holkova E Ottman MS Czuczman 2005 Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model Clin Cancer Res 11 5984 5992
17. T Hideshima D Chauhan Y Shima N Raje FE Davies YT Tai SP Treon B Lin RL Schlossman P Richardson G Muller DI Stirling KC Anderson 2000 Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2943 2950
18. E Kastritis MA Dimopoulos 2007 The evolving role of lenalidomide in the treatment of hematologic malignancies Expert Opin Pharmacother 8 497 509
19. S Lentzsch R LeBlanc K Podar F Davies B Lin T Hideshima L Catley DI Stirling KC Anderson 2003 Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo Leukemia 17 41 44
20. AF List 2005 Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS) Semin Oncol 32 S31 S35
21. JB Marriott K Dredge AG Dalgleish 2003 Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents Curr Drug Targets Immune Endocr Metabol Disord 3 181 186
22. RA Mesa A Tefferi CY Li DP Steensma 2006 Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome Leukemia 20 2063 2064
23. AA Miller D Case M Harmon P Savage G Lesser D Hurd SA Melin 2007 Phase I study of lenalidomide in solid tumors J Thorac Oncol 2 445 449
24. N Mitsiades CS Mitsiades V Poulaki D Chauhan PG Richardson T Hideshima NC Munshi SP Treon KC Anderson 2002 Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 99 4525 4530
25. MJ Morris N Pandit-Taskar CR Divgi S Bender JA O'Donoghue A Nacca P Smith-Jones L Schwartz S Slovin R Finn S Larson HI Scher 2007 Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors Clin Cancer Res 13 2707 2713
26. Moss RA, Mohile SG, Shelton G, Melia J, Petrylak DP (2007) A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). Paper presented at 2007 prostate cancer symposium abstract 89
27. A Nagler LL Lanier S Cwirla JH Phillips 1989 Comparative studies of human FcRIII-positive and negative natural killer cells J Immunol 143 3183 3191
28. F Payvandi L Wu SD Naziruddin M Haley A Parton PH Schafer RS Chen GW Muller CC Hughes DI Stirling 2005 Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT J Interferon Cytokine Res 25 604 616
29. N Raje S Kumar T Hideshima K Ishitsuka D Chauhan C Mitsiades K Podar S Le Gouill P Richardson NC Munshi DI Stirling JH Antin KC Anderson 2004 Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma Blood 104 4188 4193
30. PG Richardson CS Mitsiades T Hideshima KC Anderson 2005 Novel biological therapies for the treatment of multiple myeloma Best Pract Res Clin Haematol 18 619 634
31. MJ Robertson MA Caligiuri TJ Manley H Levine J Ritz 1990 Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis J Immunol 145 3194 3201
32. MJ Robertson RJ Soiffer SF Wolf TJ Manley C Donahue D Young SH Herrmann J Ritz 1992 Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF J Exp Med 175 779 788
33. PH Schafer AK Gandhi MA Loveland RS Chen HW Man PP Schnetkamp G Wolbring S Govinda LG Corral F Payvandi GW Muller DI Stirling 2003 Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs J Pharmacol Exp Ther 305 1222 1232
34. YT Tai XF Li L Catley R Coffey I Breitkreutz J Bae W Song K Podar T Hideshima D Chauhan R Schlossman P Richardson SP Treon IS Grewal NC Munshi KC Anderson 2005 Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications Cancer Res 65 11712 11720
35. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weler E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC (2007) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood (prepublished online Oct 9, 2007)
36. E Takahashi N Kuranaga K Satoh Y Habu N Shinomiya T Asano S Seki M Hayakawa 2007 Induction of CD16+CD56bright NK cells with antitumour cytotoxicity not only from CD16-CD56bright NK cells but also from CD16-CD56dim NK cells Scand J Immunol 65 126 138
37. D Verhelle LG Corral K Wong JH Mueller L Moutouh-de Parseval K Jensen-Pergakes PH Schafer R Chen E Glezer GD Ferguson A Lopez-Girona GW Muller HA Brady KW Chan 2007 Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells Cancer Res 67 746 755
38. Wiernik P, Lossos IS, Tuscano J, Justice G, Vose JM, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis J, Habermann T (2007) Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma. Paper presented at 2007 ASCO annual meeting abstract 8052